Prospect Venture Partners, L.P.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a 40mm pre-tied suture loop for effective soft tissue closure through minimally invasive access points as small as 4.3mm. This innovative technology eliminates the need for metal, clips, or fabrics, ensuring a complete and immediate closure without leaving foreign materials in the body. SentreHEART has received regulatory clearance for its device for soft tissue ligation and approximation in the United States, Europe, and Canada, enhancing surgical options and patient safety by reducing the risk of thromboembolism.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Incorporated in 2007 and headquartered in South San Francisco, California, the company is engaged in creating novel treatments informed by key biological pathways. Its product candidates include Aldafermin, an engineered variant of the FGF19 hormone currently in Phase 2b clinical trials for non-alcoholic steatohepatitis (NASH), and NGM313, an agonistic antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates in development include NGM395 for metabolic syndrome, NGM120 to address cancer anorexia/cachexia syndrome, NGM217 aimed at improving insulin production in diabetes patients, and NGM621 to target a protein involved in age-related macular degeneration. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and development efforts in creating impactful medicines that enhance patient health.

Nora Therapeutics is a biopharmaceutical company based in Palo Alto, California, focused on developing therapeutics for unmet needs in reproductive medicine. Founded in 1992, the company's lead product, NT100, is a novel biologic agent designed to mimic a naturally occurring protein in the female reproductive tract. NT100 aims to improve pregnancy success rates and outcomes by optimizing maternal-fetal immune tolerance, particularly for women with a history of unexplained recurrent miscarriage or multiple unsuccessful in vitro fertilization (IVF) procedures. This optimization is intended to enhance embryo implantation and maintain pregnancy.

Element Science is a medical device and digital health company that develops wearable technologies to address sudden cardiac death risk in high-risk cardiovascular patients. The company designs a wearable cardioverter defibrillator and a digital platform that combines patient-centric human factors, machine learning, and rigorous electromechanical medical device development standards. Its solutions support patients transitioning from hospital to home, providing continuous protection during daily activities such as showering and sleeping. Founded in 2011 and headquartered in San Francisco, Element Science aims to reduce avoidable mortality from heart disease through integrated sensing, analytics, and lifesaving therapy delivered via wearable technology.

NinePoint Medical, Inc. is a medical device company based in Bedford, Massachusetts, that specializes in the development of innovative optical coherence tomography (OCT) imaging systems for assessing human tissue microstructure. The company's flagship product, the NvisionVLE Imaging System, enables real-time volumetric imaging of the esophagus and bile duct, allowing physicians across various specialties—including gastroenterology, pulmonology, urology, gynecology, and ENT—to perform advanced diagnostic procedures. By providing high-resolution cross-sectional images, NinePoint's system empowers physicians to make accurate diagnoses and implement effective therapies during the same procedure, enhancing patient care and outcomes. The company markets its imaging systems through a network of distributors in the United States and internationally. Originally founded as Convergence Devices, Inc. in 2008, NinePoint Medical underwent a name change in 2009 and has since focused on advancing telepathology capabilities to improve healthcare efficiency and patient experiences.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Incorporated in 2007 and headquartered in South San Francisco, California, the company is engaged in creating novel treatments informed by key biological pathways. Its product candidates include Aldafermin, an engineered variant of the FGF19 hormone currently in Phase 2b clinical trials for non-alcoholic steatohepatitis (NASH), and NGM313, an agonistic antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates in development include NGM395 for metabolic syndrome, NGM120 to address cancer anorexia/cachexia syndrome, NGM217 aimed at improving insulin production in diabetes patients, and NGM621 to target a protein involved in age-related macular degeneration. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and development efforts in creating impactful medicines that enhance patient health.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a 40mm pre-tied suture loop for effective soft tissue closure through minimally invasive access points as small as 4.3mm. This innovative technology eliminates the need for metal, clips, or fabrics, ensuring a complete and immediate closure without leaving foreign materials in the body. SentreHEART has received regulatory clearance for its device for soft tissue ligation and approximation in the United States, Europe, and Canada, enhancing surgical options and patient safety by reducing the risk of thromboembolism.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

DFine Inc. is a medical device company that specializes in developing minimally invasive therapeutic devices aimed at treating spinal pathologies such as metastatic tumors and vertebral compression fractures. Founded in 2004 and headquartered in San Jose, California, DFine offers innovative solutions, including the STAR tumor ablation system designed for palliative treatment by targeting malignant lesions in the vertebral body. Additionally, the company provides vertebral augmentation systems for the percutaneous delivery of bone cement and vertebroplasty systems for treating pathological fractures. In July 2016, DFine became a subsidiary of Merit Medical Systems, enhancing its capacity to deliver effective therapies for spinal conditions.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Incorporated in 2007 and headquartered in South San Francisco, California, the company is engaged in creating novel treatments informed by key biological pathways. Its product candidates include Aldafermin, an engineered variant of the FGF19 hormone currently in Phase 2b clinical trials for non-alcoholic steatohepatitis (NASH), and NGM313, an agonistic antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates in development include NGM395 for metabolic syndrome, NGM120 to address cancer anorexia/cachexia syndrome, NGM217 aimed at improving insulin production in diabetes patients, and NGM621 to target a protein involved in age-related macular degeneration. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and development efforts in creating impactful medicines that enhance patient health.

Topica Pharmaceuticals, Inc. is a privately held clinical research stage pharmaceutical company dedicated to developing luliconazole for the treatment of onychomycosis, a fungal infection affecting the nails. With over 35 million Americans suffering from this condition and limited treatment options available, Topica focuses on luliconazole due to its potent antifungal properties and favorable safety profile. The drug can rapidly penetrate the nail plate, effectively reaching the infection site in the nail bed. Following a successful Phase 1/2a clinical trial in 2011 that demonstrated the drug's ability to cross the nail plate and its tolerability among patients, Topica is now concentrating on a comprehensive dose-finding study to prove the efficacy of luliconazole. The ultimate objective is to establish luliconazole as a highly effective and safe topical treatment for onychomycosis, addressing a significant unmet medical need.

Azelon Pharmaceuticals, formerly Zelos Therapeutics, a West Conshohocken, PA-based company focused on the development of novel formulations for the treatment of osteoporosis.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

SurePoint Medical, LLC is a Lawrence, Kansas-based company that specializes in providing mail-order diabetes supplies across the United States. The company focuses on delivering essential products to individuals managing diabetes, ensuring they have convenient access to the supplies they need for effective self-care. With a commitment to customer service and efficient delivery, SurePoint Medical aims to improve the quality of life for those living with diabetes by streamlining the process of obtaining necessary medical supplies.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

NinePoint Medical, Inc. is a medical device company based in Bedford, Massachusetts, that specializes in the development of innovative optical coherence tomography (OCT) imaging systems for assessing human tissue microstructure. The company's flagship product, the NvisionVLE Imaging System, enables real-time volumetric imaging of the esophagus and bile duct, allowing physicians across various specialties—including gastroenterology, pulmonology, urology, gynecology, and ENT—to perform advanced diagnostic procedures. By providing high-resolution cross-sectional images, NinePoint's system empowers physicians to make accurate diagnoses and implement effective therapies during the same procedure, enhancing patient care and outcomes. The company markets its imaging systems through a network of distributors in the United States and internationally. Originally founded as Convergence Devices, Inc. in 2008, NinePoint Medical underwent a name change in 2009 and has since focused on advancing telepathology capabilities to improve healthcare efficiency and patient experiences.

Pathwork Diagnostics, located in Redwood City, California, specializes in the development of molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in the identification of challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. Pathwork Diagnostics offers lab services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen samples, leveraging genomic information to enhance tumor classification and support oncological decision-making.

Complete Genomics is a developer of advanced DNA sequencing technology focused on human genome sequencing and analysis. The company offers a comprehensive genomics analysis platform that integrates its proprietary sequencing technology with informatics and data management software. This combination allows Complete Genomics to deliver high-quality, affordable DNA sequencing services that facilitate large-scale research into the genetic mechanisms underlying drug responses and complex diseases. By providing ready-to-use genomic data, Complete Genomics aims to enhance the capabilities of researchers in the field of genomics and contribute to advancements in personalized medicine.

DFine Inc. is a medical device company that specializes in developing minimally invasive therapeutic devices aimed at treating spinal pathologies such as metastatic tumors and vertebral compression fractures. Founded in 2004 and headquartered in San Jose, California, DFine offers innovative solutions, including the STAR tumor ablation system designed for palliative treatment by targeting malignant lesions in the vertebral body. Additionally, the company provides vertebral augmentation systems for the percutaneous delivery of bone cement and vertebroplasty systems for treating pathological fractures. In July 2016, DFine became a subsidiary of Merit Medical Systems, enhancing its capacity to deliver effective therapies for spinal conditions.

Baxano, Inc. is a medical device company specializing in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Founded in 2005 and based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in the foramen, lateral recess, and central canal, catering to patients with varying degrees of spinal stenosis. Baxano's product lineup includes the Neuro Check device, which enables surgeons to verify safe positioning against the bone while ensuring the nerve is adequately protected. Additionally, it features the MicroBlade Shaver, an instrument for removing impinging bone and ligament, along with essential accessories such as guidewires, probes, and distal handles.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company's primary technology is Pro/PEG, a bioadhesive polymer hydrogel designed to enhance the healing process. Neomend specializes in a combination wound sealant and adhesion barrier product that can be utilized during minimally invasive and laparoscopic procedures, improving patient outcomes and recovery times. Through its advanced technological solutions, Neomend aims to address critical needs in surgical wound management.

DFine Inc. is a medical device company that specializes in developing minimally invasive therapeutic devices aimed at treating spinal pathologies such as metastatic tumors and vertebral compression fractures. Founded in 2004 and headquartered in San Jose, California, DFine offers innovative solutions, including the STAR tumor ablation system designed for palliative treatment by targeting malignant lesions in the vertebral body. Additionally, the company provides vertebral augmentation systems for the percutaneous delivery of bone cement and vertebroplasty systems for treating pathological fractures. In July 2016, DFine became a subsidiary of Merit Medical Systems, enhancing its capacity to deliver effective therapies for spinal conditions.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Incorporated in 2007 and headquartered in South San Francisco, California, the company is engaged in creating novel treatments informed by key biological pathways. Its product candidates include Aldafermin, an engineered variant of the FGF19 hormone currently in Phase 2b clinical trials for non-alcoholic steatohepatitis (NASH), and NGM313, an agonistic antibody in Phase 1b trials for type 2 diabetes and NASH. Other candidates in development include NGM395 for metabolic syndrome, NGM120 to address cancer anorexia/cachexia syndrome, NGM217 aimed at improving insulin production in diabetes patients, and NGM621 to target a protein involved in age-related macular degeneration. NGM Biopharmaceuticals collaborates with Merck Sharp & Dohme Corp. to advance its research and development efforts in creating impactful medicines that enhance patient health.

Lux Biosciences, established in 2005 and headquartered in Jersey City, New Jersey, is a biotechnology company focused on developing innovative treatments for ophthalmic diseases. Its product pipeline includes LX201, an implantable device releasing cyclosporine A for extended periods; Luveniq, an oral calcineurin inhibitor voclosporin; LX212, a bioerodible polymer implant containing voclosporin; and LX214, a topical nanomicellar formulation of voclosporin for dry eye therapy. These products aim to address serious ophthalmic conditions, improving patient outcomes through effective and convenient treatment options.

Alvine Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing biologics for autoimmune and inflammatory diseases, with a particular emphasis on celiac disease. The company's lead product, ALV003, is an orally administered mixture of two gluten-specific proteases designed to degrade gluten, the primary immunologic trigger for celiac disease. In addition to ALV003, Alvine is also developing other proteases that target celiac disease, including Transglutaminase 2 (TG2) and the HLADQ2 heterodimer. Founded in 2005 and based in San Carlos, California, Alvine Pharmaceuticals operates as a subsidiary of ImmunogenX, LLC.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing and advancing clinical-stage oncology drug candidates. Owned by Celgene, the company specializes in hematological malignancies and is best known for its lead compound, romidepsin. This late-stage oncology drug is a histone deacetylase (HDAC) inhibitor that has demonstrated potential efficacy in treating various forms of T-cell lymphomas and other hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester Pharmaceuticals retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of multiple HDAC classes in preclinical studies. The company aims to progress its drug candidates through regulatory approval and commercialization to address unmet medical needs in oncology.

Complete Genomics is a developer of advanced DNA sequencing technology focused on human genome sequencing and analysis. The company offers a comprehensive genomics analysis platform that integrates its proprietary sequencing technology with informatics and data management software. This combination allows Complete Genomics to deliver high-quality, affordable DNA sequencing services that facilitate large-scale research into the genetic mechanisms underlying drug responses and complex diseases. By providing ready-to-use genomic data, Complete Genomics aims to enhance the capabilities of researchers in the field of genomics and contribute to advancements in personalized medicine.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary prescription therapeutics for significant medical conditions with unmet needs and high levels of patient dissatisfaction. The company primarily targets diseases and disorders in the central nervous system therapeutic area. Currently, Somaxon promotes Silenor, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, Somaxon has been involved in developing products for other conditions, including middle ear infections, head lice, and cough and cold. The company's efforts are directed toward in-licensing, developing, and marketing both proprietary products and late-stage candidates to address various health challenges.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development and commercialization of innovative therapeutics for thrombosis, hematologic disorders, and inflammation. Founded in 2003, Portola's lead product, Andexxa, serves as an antidote for patients treated with rivaroxaban and apixaban. The company's portfolio also includes Bevyxxa, an oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical illnesses. Additionally, Portola is developing investigational therapies such as cerdulatinib, a dual inhibitor targeting spleen tyrosine kinase and Janus kinases for hematologic cancers, and various Syk inhibitors for chronic inflammatory diseases. Portola collaborates with several major pharmaceutical companies to enhance its research and development efforts. As of July 2020, Portola operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Visiogen, Inc. is an ophthalmic medical device company focused on creating innovative vision solutions for cataract patients, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless vision experience across near, intermediate, and distance ranges without the need for corrective eyewear. To enhance surgical efficiency, the Synchrony IOL is supplied in a pre-loaded injector, minimizing lens handling during procedures. This advanced technology has received CE Mark approval in Europe and is currently undergoing clinical trials in the United States, reflecting Visiogen's commitment to improving patient outcomes in cataract surgery.

Satori Pharmaceuticals is a neuroscience company focused on the discovery and development of disease-modifying therapies for Alzheimer's disease, Parkinson's disease and other neurodegenerative disorders.

DFine Inc. is a medical device company that specializes in developing minimally invasive therapeutic devices aimed at treating spinal pathologies such as metastatic tumors and vertebral compression fractures. Founded in 2004 and headquartered in San Jose, California, DFine offers innovative solutions, including the STAR tumor ablation system designed for palliative treatment by targeting malignant lesions in the vertebral body. Additionally, the company provides vertebral augmentation systems for the percutaneous delivery of bone cement and vertebroplasty systems for treating pathological fractures. In July 2016, DFine became a subsidiary of Merit Medical Systems, enhancing its capacity to deliver effective therapies for spinal conditions.

Baxano, Inc. is a medical device company specializing in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Founded in 2005 and based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in the foramen, lateral recess, and central canal, catering to patients with varying degrees of spinal stenosis. Baxano's product lineup includes the Neuro Check device, which enables surgeons to verify safe positioning against the bone while ensuring the nerve is adequately protected. Additionally, it features the MicroBlade Shaver, an instrument for removing impinging bone and ligament, along with essential accessories such as guidewires, probes, and distal handles.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

DFine Inc. is a medical device company that specializes in developing minimally invasive therapeutic devices aimed at treating spinal pathologies such as metastatic tumors and vertebral compression fractures. Founded in 2004 and headquartered in San Jose, California, DFine offers innovative solutions, including the STAR tumor ablation system designed for palliative treatment by targeting malignant lesions in the vertebral body. Additionally, the company provides vertebral augmentation systems for the percutaneous delivery of bone cement and vertebroplasty systems for treating pathological fractures. In July 2016, DFine became a subsidiary of Merit Medical Systems, enhancing its capacity to deliver effective therapies for spinal conditions.

Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.

SurgRx is a developer of laparoscopic vessel fusion tools for surgical hemostasis.

Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.

Vitae Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Washington, Pennsylvania, that specializes in discovering and developing novel small molecule drugs aimed at addressing significant unmet medical needs. Founded in 2001, Vitae's product pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis, and VTP-38543, which is in Phase IIa trials for atopic dermatitis. The company is also advancing VTP-34072 in Phase II trials for type 2 diabetes and VTP-38443 for acute coronary syndrome, as well as BI 1147560 for Alzheimer's disease. Vitae Pharmaceuticals utilizes a structure-based drug-design platform known as Contour to develop its compounds, targeting large markets with chronic conditions, including chronic kidney disease and atherosclerosis. In 2016, Vitae became a subsidiary of Allergan plc.

Neomend is a biomedical device company focused on developing and commercializing innovative surgical wound healing products. The company's primary technology is Pro/PEG, a bioadhesive polymer hydrogel designed to enhance the healing process. Neomend specializes in a combination wound sealant and adhesion barrier product that can be utilized during minimally invasive and laparoscopic procedures, improving patient outcomes and recovery times. Through its advanced technological solutions, Neomend aims to address critical needs in surgical wound management.

Roxro Pharma, Inc. is a biopharmaceutical company focused on developing innovative drugs for pain management. Founded in 1999 and headquartered in Menlo Park, California, the company offers products designed to address various types of pain. Notable among its offerings is ROX-888, an intranasal formulation aimed at treating dental and postoperative pain. Additionally, Roxro Pharma is advancing ROX-828, a non-opioid and non-triptan intranasal product specifically for the treatment of migraines. The company's commitment to providing effective pain relief options positions it as a significant player in the pharmaceutical industry.

SurgRx is a developer of laparoscopic vessel fusion tools for surgical hemostasis.

Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.

Aspen MedTech is a medical device incubator based in Bellevue, Washington.

Amira Pharmaceuticals is a small molecule pharmaceutical company dedicated to the discovery and early development of innovative drugs for treating inflammatory diseases. The company leverages its team’s expertise in bioactive lipid pathways and complex signaling processes to address various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular diseases, and fibrotic diseases. Through its focused research efforts, Amira Pharmaceuticals aims to create effective therapeutic solutions that can significantly improve patient outcomes in these areas.

Visiogen, Inc. is an ophthalmic medical device company focused on creating innovative vision solutions for cataract patients, including those with presbyopia. The company's flagship product is the Synchrony dual optic accommodating intraocular lens (IOL), designed to deliver a seamless vision experience across near, intermediate, and distance ranges without the need for corrective eyewear. To enhance surgical efficiency, the Synchrony IOL is supplied in a pre-loaded injector, minimizing lens handling during procedures. This advanced technology has received CE Mark approval in Europe and is currently undergoing clinical trials in the United States, reflecting Visiogen's commitment to improving patient outcomes in cataract surgery.

Amira Pharmaceuticals is a small molecule pharmaceutical company dedicated to the discovery and early development of innovative drugs for treating inflammatory diseases. The company leverages its team’s expertise in bioactive lipid pathways and complex signaling processes to address various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular diseases, and fibrotic diseases. Through its focused research efforts, Amira Pharmaceuticals aims to create effective therapeutic solutions that can significantly improve patient outcomes in these areas.

Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering therapies for rare and orphan diseases. It specializes in oral pharmacological chaperones—small molecules that bind, stabilize, and enhance activity of misfolded enzymes—to treat lysosomal storage disorders such as Fabry and Pompe disease, and it explores combination approaches with enzyme replacement therapy. The company maintains a growing pipeline targeting additional lysosomal diseases, including Gaucher, and collaborates with academic and clinical partners to advance its programs. Amicus was founded in 2002 and is headquartered in Cranbury, New Jersey.

Alvine Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing biologics for autoimmune and inflammatory diseases, with a particular emphasis on celiac disease. The company's lead product, ALV003, is an orally administered mixture of two gluten-specific proteases designed to degrade gluten, the primary immunologic trigger for celiac disease. In addition to ALV003, Alvine is also developing other proteases that target celiac disease, including Transglutaminase 2 (TG2) and the HLADQ2 heterodimer. Founded in 2005 and based in San Carlos, California, Alvine Pharmaceuticals operates as a subsidiary of ImmunogenX, LLC.

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Pathwork Diagnostics, located in Redwood City, California, specializes in the development of molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in the identification of challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. Pathwork Diagnostics offers lab services for various specimen types, including formalin-fixed, paraffin-embedded, and frozen samples, leveraging genomic information to enhance tumor classification and support oncological decision-making.

Cogentus Pharmaceuticals, Inc., a pharmaceutical company, develops prescription pharmaceutical products in North America and Europe. It develops CGT-2168, an oral formulation that combines clopidogrel with a gastroprotectant, which reduces the gastrointestinal side effects associated with dual antiplatelet therapy. The company was founded in 2006 and is based in Menlo Park, California. On January 16, 2009, Cogentus Pharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Northern District of California.

DFine Inc. is a medical device company that specializes in developing minimally invasive therapeutic devices aimed at treating spinal pathologies such as metastatic tumors and vertebral compression fractures. Founded in 2004 and headquartered in San Jose, California, DFine offers innovative solutions, including the STAR tumor ablation system designed for palliative treatment by targeting malignant lesions in the vertebral body. Additionally, the company provides vertebral augmentation systems for the percutaneous delivery of bone cement and vertebroplasty systems for treating pathological fractures. In July 2016, DFine became a subsidiary of Merit Medical Systems, enhancing its capacity to deliver effective therapies for spinal conditions.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development and commercialization of innovative therapeutics for thrombosis, hematologic disorders, and inflammation. Founded in 2003, Portola's lead product, Andexxa, serves as an antidote for patients treated with rivaroxaban and apixaban. The company's portfolio also includes Bevyxxa, an oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical illnesses. Additionally, Portola is developing investigational therapies such as cerdulatinib, a dual inhibitor targeting spleen tyrosine kinase and Janus kinases for hematologic cancers, and various Syk inhibitors for chronic inflammatory diseases. Portola collaborates with several major pharmaceutical companies to enhance its research and development efforts. As of July 2020, Portola operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Hansen Medical, Inc. specializes in the development, manufacture, and sale of medical robotics aimed at enhancing the positioning, manipulation, and control of catheters and catheter-based technologies. The company offers the Sensei systems and Artisan Control Catheters, which are used in electrophysiology procedures to improve catheter navigation and control. Additionally, Hansen Medical provides the CoHesion 3D Visualization Module, a software tool that enhances physicians' ability to visualize catheter placement in three dimensions. Another key product is the Magellan Robotic System, which facilitates remote navigation and vessel cannulation using a telescoping, robotically steerable catheter. The company markets and supports its products through a combination of direct sales, distributors, and sales representatives. Founded in 2002 and headquartered in Mountain View, California, Hansen Medical operates as a subsidiary of Auris Surgical Robotics, Inc. since July 2016.

Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.

Roxro Pharma, Inc. is a biopharmaceutical company focused on developing innovative drugs for pain management. Founded in 1999 and headquartered in Menlo Park, California, the company offers products designed to address various types of pain. Notable among its offerings is ROX-888, an intranasal formulation aimed at treating dental and postoperative pain. Additionally, Roxro Pharma is advancing ROX-828, a non-opioid and non-triptan intranasal product specifically for the treatment of migraines. The company's commitment to providing effective pain relief options positions it as a significant player in the pharmaceutical industry.

Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering therapies for rare and orphan diseases. It specializes in oral pharmacological chaperones—small molecules that bind, stabilize, and enhance activity of misfolded enzymes—to treat lysosomal storage disorders such as Fabry and Pompe disease, and it explores combination approaches with enzyme replacement therapy. The company maintains a growing pipeline targeting additional lysosomal diseases, including Gaucher, and collaborates with academic and clinical partners to advance its programs. Amicus was founded in 2002 and is headquartered in Cranbury, New Jersey.

Amira Pharmaceuticals is a small molecule pharmaceutical company dedicated to the discovery and early development of innovative drugs for treating inflammatory diseases. The company leverages its team’s expertise in bioactive lipid pathways and complex signaling processes to address various conditions, including asthma, chronic obstructive pulmonary disease, cardiovascular diseases, and fibrotic diseases. Through its focused research efforts, Amira Pharmaceuticals aims to create effective therapeutic solutions that can significantly improve patient outcomes in these areas.

Vitae Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Washington, Pennsylvania, that specializes in discovering and developing novel small molecule drugs aimed at addressing significant unmet medical needs. Founded in 2001, Vitae's product pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis, and VTP-38543, which is in Phase IIa trials for atopic dermatitis. The company is also advancing VTP-34072 in Phase II trials for type 2 diabetes and VTP-38443 for acute coronary syndrome, as well as BI 1147560 for Alzheimer's disease. Vitae Pharmaceuticals utilizes a structure-based drug-design platform known as Contour to develop its compounds, targeting large markets with chronic conditions, including chronic kidney disease and atherosclerosis. In 2016, Vitae became a subsidiary of Allergan plc.

Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.

Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing proprietary prescription therapeutics for significant medical conditions with unmet needs and high levels of patient dissatisfaction. The company primarily targets diseases and disorders in the central nervous system therapeutic area. Currently, Somaxon promotes Silenor, the first and only nonscheduled prescription medication approved in the United States for the treatment of sleep maintenance insomnia. In addition to its focus on insomnia, Somaxon has been involved in developing products for other conditions, including middle ear infections, head lice, and cough and cold. The company's efforts are directed toward in-licensing, developing, and marketing both proprietary products and late-stage candidates to address various health challenges.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing and advancing clinical-stage oncology drug candidates. Owned by Celgene, the company specializes in hematological malignancies and is best known for its lead compound, romidepsin. This late-stage oncology drug is a histone deacetylase (HDAC) inhibitor that has demonstrated potential efficacy in treating various forms of T-cell lymphomas and other hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester Pharmaceuticals retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of multiple HDAC classes in preclinical studies. The company aims to progress its drug candidates through regulatory approval and commercialization to address unmet medical needs in oncology.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapies that address significant unmet medical needs, particularly in the realm of central nervous system disorders. The company markets HETLIOZ, a treatment for non-24-hour sleep-wake disorders and nighttime disturbances in Smith-Magenis Syndrome, and Fanapt, which is used for schizophrenia. Vanda's pipeline includes several investigational products such as HETLIOZ for jet lag disorder and delayed sleep phase disorder, Tradipitant for atopic dermatitis and motion sickness, and VTR-297, a histone deacetylase inhibitor for hematologic malignancies. The company is also exploring therapies for various psychiatric disorders and conditions related to cystic fibrosis. Vanda’s products are available in the United States, Europe, and Israel, reflecting its commitment to improving patient outcomes through innovative treatment options. Founded in 2002, Vanda is headquartered in Washington, D.C.

Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

SurgRx is a developer of laparoscopic vessel fusion tools for surgical hemostasis.

Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. Our product candidates are novel proteins known as single-chain polypeptides and are designed using our SMIPTM custom drug assembly technology.

Rejuvenon a biopharmaceutical company committed developing and commercializing promising compounds for treatment of oncologic diseases.

IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected with Hepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc.

Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering therapies for rare and orphan diseases. It specializes in oral pharmacological chaperones—small molecules that bind, stabilize, and enhance activity of misfolded enzymes—to treat lysosomal storage disorders such as Fabry and Pompe disease, and it explores combination approaches with enzyme replacement therapy. The company maintains a growing pipeline targeting additional lysosomal diseases, including Gaucher, and collaborates with academic and clinical partners to advance its programs. Amicus was founded in 2002 and is headquartered in Cranbury, New Jersey.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of therapeutic aptamers for the prevention and treatment of both chronic and acute diseases. Established in 2000, Archemix is known for its aptamer product candidates, including ARC1779, which is aimed at treating thrombotic microangiopathies and is also relevant for use in carotid endarterectomy procedures. In addition to its work in these areas, the company is developing aptamer therapeutics targeting various conditions in the fields of cardiovascular health, hematology, and oncology.

Jazz Pharmaceuticals is a biopharmaceutical company based in Ireland that specializes in developing and commercializing innovative treatments for neurology and oncology, particularly in underserved markets. The company has nine approved drugs, including Xyrem and Xywav, which treat narcolepsy, and Zepzelca, Rylaze, and Vyxeos, aimed at various cancers such as metastatic small cell lung cancer and acute leukemias. Additionally, Jazz acquired GW Pharmaceuticals, enhancing its portfolio with Epidiolex, a treatment for severe, rare forms of epilepsy. Other notable products include Cystadane for homocystinuria and Antizol for ethylene glycol and methanol poisoning. Jazz Pharmaceuticals is committed to addressing significant medical needs through its targeted therapies.

Phylogix Inc. is a biotechnology company focused on tissue protection and oncology. The company develops lectin-based drugs focused on tissue protection, oncology, and immunology. It also involves in the development of FRIL, an agent to protect patients from the toxic side-effects of chemotherapy. Phylogix Inc. is based in Scarborough, Maine.

Vitae Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Fort Washington, Pennsylvania, that specializes in discovering and developing novel small molecule drugs aimed at addressing significant unmet medical needs. Founded in 2001, Vitae's product pipeline includes VTP-43742, currently in Phase I clinical trials for autoimmune disorders such as psoriasis and multiple sclerosis, and VTP-38543, which is in Phase IIa trials for atopic dermatitis. The company is also advancing VTP-34072 in Phase II trials for type 2 diabetes and VTP-38443 for acute coronary syndrome, as well as BI 1147560 for Alzheimer's disease. Vitae Pharmaceuticals utilizes a structure-based drug-design platform known as Contour to develop its compounds, targeting large markets with chronic conditions, including chronic kidney disease and atherosclerosis. In 2016, Vitae became a subsidiary of Allergan plc.

Portola Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, specializing in the development and commercialization of innovative therapeutics for thrombosis, hematologic disorders, and inflammation. Founded in 2003, Portola's lead product, Andexxa, serves as an antidote for patients treated with rivaroxaban and apixaban. The company's portfolio also includes Bevyxxa, an oral Factor Xa inhibitor designed to prevent venous thromboembolism in adults with acute medical illnesses. Additionally, Portola is developing investigational therapies such as cerdulatinib, a dual inhibitor targeting spleen tyrosine kinase and Janus kinases for hematologic cancers, and various Syk inhibitors for chronic inflammatory diseases. Portola collaborates with several major pharmaceutical companies to enhance its research and development efforts. As of July 2020, Portola operates as a subsidiary of Alexion Pharmaceuticals, Inc.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Rinat Neuroscience, established in 2001 as a spin-out from Genentech, specializes in the development of protein-based therapeutics targeting diseases and disorders of the nervous system. The company leverages over 15 years of research and development support from Genentech to advance its innovative pipeline. Rinat focuses on creating antibody drugs for various conditions, including pain, Alzheimer's disease, obesity, diabetes, and neuropathies. In addition to these therapeutic areas, Rinat is engaged in developing novel disease-modifying therapies aimed at modulating neuronal function and preventing or reversing damage to specific populations of neurons affected by these diseases.

Tercica Inc., a biotechnology company, engages in the development and commercialization of therapeutics for the treatment of endocrine and metabolic diseases. Its products include Increlex, an rDNA origin injection for the long-term treatment of children with short stature due to severe primary IGFD; and Somatuline Depot, a lanreotide injection for the treatment of adults with acromegaly. Tercica Inc. has strategic partnerships with Genentech and Ipsen SA. The company was founded in 2002 and is based in Brisbane, California. As of October 16, 2008, Tercica Inc. operates as a subsidiary of Ipsen S.A.

Opus Medical designs and manufactures tissue-to-bone and tissue-to tissue repair systems.

Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.

Biospect, Inc. is a South San Francisco-based life sciences technology company focused on developing minimally invasive solutions for identifying and analyzing protein biomarker patterns. These patterns are crucial for differentiating various biological states, which aids in diagnosing and managing diseases, as well as facilitating drug development. The company integrates proprietary technologies in separations, detection, and informatics to create a comprehensive system designed for medical research applications. By advancing the capabilities of biomarker analysis, Biospect aims to enhance the effectiveness of disease management and therapeutic innovation.

Archemix Corp. is a biotechnology company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of therapeutic aptamers for the prevention and treatment of both chronic and acute diseases. Established in 2000, Archemix is known for its aptamer product candidates, including ARC1779, which is aimed at treating thrombotic microangiopathies and is also relevant for use in carotid endarterectomy procedures. In addition to its work in these areas, the company is developing aptamer therapeutics targeting various conditions in the fields of cardiovascular health, hematology, and oncology.

Infinity Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. Its lead product, eganelisib, is an oral immuno-oncology agent designed to reprogram macrophages and address immune suppression in cancer. Infinity is conducting multiple clinical studies, including the global MARIO-275 trial, which investigates eganelisib in combination with Opdivo® for patients with urothelial cancer. The company is also exploring eganelisib in various combinations for front-line treatment in advanced cancers, including triple-negative breast cancer and renal cell carcinoma, evaluating it alongside other therapeutics such as Tecentriq® and Abraxane®. Additionally, Infinity is collaborating with Arcus Biosciences to assess a novel regimen combining eganelisib with etrumadenant and Doxil® in advanced triple-negative breast cancer patients. The company is committed to developing treatments for various hematologic malignancies and solid tumors, leveraging its strategic partnerships to advance its oncology programs.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Signature BioScience Inc. was the first biotechnology company based in San Francisco. It was formed in 1998 but closed in 2003 due to lack of funding. Before Signature was dissolved, it had just completed Phase II trials on Digitoxin, which the company was pursuing as an anti-cancer compound. However, the company's core competency was developing biotechnology tools that would be used to identify highly qualified pre-clinical leads.

Metreo is a software company based in Palo Alto, California, specializing in profit optimization solutions for Global 2000 manufacturers, distributors, and service providers. The company offers an integrated pricing optimization platform that enhances pricing decisions and execution by streamlining the pricing process. By enabling clients to set appropriate price targets, evaluate customer sales requests, and recommend profitable responses, Metreo's software helps organizations maximize their profit margins. The platform demystifies pricing strategies and fosters disciplined execution, ultimately allowing businesses to improve their financial outcomes by reducing costs and increasing margins.

Nanosys, Inc. is a company that specializes in the development and manufacturing of quantum dot technology aimed at enhancing high-definition viewing experiences across various display applications. Founded in 2001 and headquartered in Milpitas, California, Nanosys produces Quantum Dot Concentrate materials and Quantum Dot Enhancement films that improve the performance of a wide range of consumer electronics, including televisions, tablets, and smartphones. The company's quantum dots are nanoscale semiconductors that enable displays to achieve greater brightness and a wider color gamut, resulting in more lifelike images. This technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs. Nanosys has seen significant adoption of its technology, with over 20 million devices shipped in numerous products, thus contributing to advancements in the display industry.